Muscular regenerative capacity

Muscular regenerative capacity is a physiological process rather than a single molecular target. It represents the innate ability of skeletal muscle to repair itself following injury or in response to degenerative diseases, a process primarily mediated by a resident stem cell population known as satellite cells (Campion, 1984; Dumont et al., 2015). Upon muscle damage, these satellite cells activate, proliferate, and differentiate into myoblasts, which then fuse to form new myofibers or repair existing ones (Chargé & Marchand, 2004). This capacity is progressively impaired in conditions such as Duchenne muscular dystrophy (DMD) and age-related sarcopenia, where the pool of satellite cells may become exhausted or the systemic environment becomes inhibitory (Scharner & Zammit, 2011). While not a discrete receptor or enzyme, the concept is central to drug discovery efforts that target molecular inhibitors of this process, most notably Myostatin (GDF-8) and Activin A, which act through the ActRIIB receptor to suppress muscle growth (Lee & McPherron, 2001). Consequently, pharmacological agents like Bimagrumab or Apitegromab aim to restore or enhance this regenerative capacity by neutralizing these inhibitory signals to improve muscle mass and physical function in patients with muscle-wasting disorders.

Other names

Muscle regenerationMyogenic potentialSkeletal muscle repairMyogenic capacity

Therapeutic interventions targeting muscular regenerative capacity typically involve the inhibition of negative regulators of muscle growth, such as the Myostatin (GDF-8)/Activin signaling pathway, or the stimulation of pro-myogenic pathways like IGF-1/AKT/mTOR to enhance satellite cell activation and myofiber hypertrophy.